MIRMMirum Pharmaceuticals, Inc.

1. Oct 13, 2026Announcement of Data from the Phase 3 EXPAND Study of LIVMARLI (maralixibat) in Ultra-Rare Cholestatic Liver Diseases On October 12, 2026, Mirum Pharmaceuticals, Inc. (the “Company”) announced topline results from the Phase 3 EXPAND study evaluating LIVMARLI (maralixibat) (“Livmarli”) for the treatment of cholestatic …Other event · Form 8-K
2. Sep 28, 2026Approval of Atebrioz On September 25, 2026, Mirum Pharmaceuticals, Inc. (the “Company”) and Incyte Corporation (“Incyte”) announced that the U.S. Food and Drug Administration (“FDA”) approved Atebrioz™ (zilurgisertib) tablets to reduce the volume of total new heterotopic ossification (“HO”) in adult and pediatric …Other event · Form 8-K
3. Sep 8, 2026On September 8, 2026, Mirum Pharmaceuticals, Inc. (the “Company”) announced that, on September 2, 2026, the Company’s Board of Directors appointed Rob Myers, M.D., to succeed Joanne Quan, M.D., as the Company’s Chief Medical Officer, effective upon Dr. Myers’ beginning employment with the Company, which employment is …Director or officer change · Form 8-K
4. Aug 5, 2026Mirum Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update.Earnings release · press release
5. May 18, 2026Indenture and Notes On May 15, 2026, Mirum Pharmaceuticals, Inc. (the “Company”) issued $690.0 million aggregate principal amount of its 0.00% Convertible Senior Notes due 2032 (the “Notes”), which includes the full exercise of the initial purchasers’ option to purchase up to an additional $90.0 million aggregate …Material agreement entered · Form 8-K
6. May 6, 2026Mirum Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update.Earnings release · press release
7. May 4, 2026On May 4, 2026, Mirum Pharmaceuticals, Inc. (the “Company”) announced the primary endpoint was met in the VISTAS Phase 2b study evaluating volixibat, an investigational oral ileal bile acid transporter (“IBAT”) inhibitor, in patients with primary sclerosing cholangitis (“PSC”)Other event · Form 8-K
8. Apr 27, 2026On April 27, 2026, Mirum Pharmaceuticals, Inc. (the “Company”) announced the primary endpoint was met in the Phase 2b portion of the AZURE-1 study evaluating brelovitug, an investigational monoclonal antibody designed to bind hepatitis B surface antigen (HBsAg), for the treatment of chronic hepatitis delta virus (HDV)Other event · Form 8-K
9. Apr 8, 2026Index to Consolidated Financial Statements.Material event (exhibits only) · press release
10. Feb 25, 2026Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2025 Results and Provides Business Update.Earnings release · press release
11. Jan 26, 2026On January 23, 2026, Mirum Pharmaceuticals, Inc. (the “Company”) completed the previously announced acquisition of Bluejay Therapeutics, Inc., a Delaware corporation (“Target”), contemplated by the Agreement and Plan of Merger and Reorganization, dated December 6, 2025 (the “Merger Agreement”), by and among the …Acquisition or disposition completed · Form 8-K

Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.